Image Guided Radiation Therapy Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Image Guided Radiation Therapy (IGRT) encompasses imaging modalities and software integrated with radiation delivery systems, principally linear accelerators (LINACs), to verify tumor position before and during each treatment session. At approximately $10.0 billion in 2025, the global market reflects the combined value of imaging hardware, treatment planning software, LINAC systems with embedded IGRT capabilities, and associated services. The market is expanding at roughly 5.5% annually, a pace supported by the worldwide growth in cancer caseloads and the clinical imperative to deliver radiation with sub-millimeter accuracy.

• •Market valued at ~$10.0 billion globally in 2025; projected compound annual growth rate of approximately 5.5%
• •Core technologies include cone-beam computed tomography (CBCT), MRI-guided radiotherapy, and kilovoltage/megavoltage imaging integrated with LINAC platforms
• •Demand is anchored by clinical evidence that image guidance reduces toxicity and enables dose escalation, improving tumor control rates

The International Agency for Research on Cancer estimates that global cancer incidence continues to climb, with roughly 20 million new cases diagnosed annually, directly fueling demand for radiotherapy, including IGRT, as a cornerstone of cancer treatment. Aging demographics in developed and developing economies alike mean a growing patient population eligible for radiotherapy, while simultaneous advances in LINAC design, detector technology, and treatment planning algorithms are making IGRT more accessible and clinically effective. Reimbursement expansion in several key markets and greater physician familiarity with IGRT's dosimetric benefits further accelerate adoption.

• •Rising global cancer incidence, with radiotherapy recommended for more than half of all cancer patients at some point in their disease course
• •Aging populations worldwide expanding the pool of patients eligible for radiation therapy, particularly in emerging healthcare systems
• •Technological improvements in LINAC gating, real-time tracking, and hybrid MRI-LINAC platforms broadening the range of tumors amenable to high-precision radiotherapy

The market is commonly segmented by product type, hardware (LINACs, proton therapy systems, imaging attachments) and software (treatment planning, image registration, adaptive radiotherapy), and by end user (hospitals, cancer centers, and ambulatory surgical centers). Geographically, North America holds the largest share, supported by high healthcare spending, established cancer center networks, and early adoption of premium imaging technology. Asia-Pacific is the fastest-growing region, driven by rapid healthcare infrastructure development in China and India, government investment in oncology capacity, and increasing multinational presence in regional tenders.

• •North America commands the largest regional share, with the U.S. representing the single biggest national market due to advanced hospital systems and favorable reimbursement frameworks
• •Asia-Pacific is projected as the fastest-growing region, with China, India, Japan, and South Korea collectively accounting for a rising share of global LINAC and IGRT installations
• •Software and imaging-verification solutions are outpacing standalone hardware growth as AI-assisted targeting and adaptive planning become standard differentiators

What are the recent trends and outlook?

MRI-guided radiotherapy (MR-LINAC) is the most transformative near-term trend, enabling real-time soft-tissue visualization that overcomes the limitations of conventional CBCT and opens new indications for adaptive treatment. AI and machine learning are increasingly embedded in image registration, auto-contouring, and dose-prediction tools, reducing planning time and improving consistency. Over the medium term, the convergence of diagnostics and therapeutics, hybrid imaging suites and theranostic workflows, is likely to blur the boundary between imaging departments and radiation therapy, while digital twin and synthetic data approaches may further personalize treatment planning.

• •MRI-guided LINAC systems (Siemens Healthineers MRIdian, Elekta Unity) are gaining clinical adoption, supported by growing evidence for adaptive re-planning in abdominal and pelvic tumors
• •AI-powered image analysis, automated organ-at-risk delineation, and predictive quality assurance tools are becoming standard features in next-generation IGRT platforms
• •Hybrid treatment environments combining PET, MRI, and multi-energy LINACs in single suites are emerging as a differentiating investment priority for leading cancer centers